Related Experiment Video
Updated: Jan 8, 2026
05:47
Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling
Published on: February 12, 2019
21.9K
Gene modifiers of lung disease
1Cystic Fibrosis/Pulmonary Research and Treatment Center, 7011 Thurston-Bowles Bldg., CB# 7248, University of North Carolina, Chapel Hill, NC 27599-7248, USA. knowles@med.unc.edu
Current Opinion in Pulmonary Medicine
|October 21, 2006
Summary
Genetic modifiers significantly impact cystic fibrosis lung disease severity, influencing over half of the variability. Identifying these non-CFTR genes offers new therapeutic avenues for this genetic condition.
Area of Science:
- Genetics
- Pulmonology
- Medical Research
Background:
- Cystic fibrosis (CF) is a genetic disorder caused by CFTR gene mutations.
- Lung disease severity in CF patients shows significant variability.
- Previous studies on genetic modifiers were limited by size and methodology.
Purpose of the Study:
- To identify non-CFTR genetic factors (modifier genes) influencing cystic fibrosis lung disease severity.
- To understand the genetic basis of variability in CF lung disease.
- To explore novel therapeutic targets for CF.
Main Methods:
- Establishment of large-scale gene-modifier studies.
- Utilizing specialized quantitative methods for pulmonary disease severity.
- Employing high-resolution, whole-genome scans with genetic markers (single-nucleotide polymorphisms).
Main Results:
- Non-CFTR genetic variants account for at least 50% of pulmonary disease severity variability.
- Transforming growth factor beta1 genetic variation demonstrably modifies CF lung disease severity.
- Emerging data from large gene-modifier studies are providing new insights.
Conclusions:
- Ongoing efforts within the CF community to identify key gene modifiers.
- Candidate genes are under active investigation.
- Advanced genomic technologies are enabling precise identification of modifier genes and chromosomal regions for novel CF therapies.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.2K
01:33Cancer-Critical Genes I: Proto-oncogenes
11.1K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.1K
01:24Cystic Fibrosis: Management
443
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
443
02:04Covalently Linked Protein Regulators
8.6K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
8.6K
01:17Other Pulmonary Disorders
1.5K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.5K